TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03965871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine DPI - low dose
Description: Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine DPI - medium dose
Description: Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine DPI - high dose
Description: Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DPI
Description: Placebo DPI is to be administered via dry powder inhaler.
Study: NCT01645865

Intervention type: BEHAVIORAL
Intervention: Control
Description: Health facilities where PMTCT services are available in the traditional clinical setting with HIV testing and counseling, PMTCT support, and enrollment in care and treatment.

Intervention type: BEHAVIORAL
Intervention: Intervention
Description: In addition to the 'Standard of Care', HIV-infected pregnant women and male partners within the PMTCT program are engaged in multi-directional mobile communication for PMTCT promotion with health care providers.
Study: NCT01999907

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 100,000IU cholecalciferol given in a 2ml dose by mouth at baseline.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: daily vitamin D supplement
Description: Each group receives a daily vitamin D supplement for 6 months, providing 400IU per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: daily vitamin D supplement
Description: Each group receives a daily vitamin D supplement for 6 months, providing 400IU per day.
Study: NCT03068260

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound-guided nerve block
Description: Transmuscular quadratus lumborum block, ultrasound-guided

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: intravenously administered morphine via PCA-pump

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: intravenously administered morphine via PCA-pump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled analgesia
Description: PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Patient-controlled analgesia
Description: PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.
Study: NCT00134082

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KGEL vaccine
Description: Vaccine was administered at weeks 0, 4, 8, 12, 16, and 24 at a dose of 1 x 10\^8 cells per dose. The first dose was given on Day +1.
Study: NCT04163653

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-contrast MRI
Description: Classification and characterization of the lymphatic vasculature using non-contrast MRI.

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-contrast MRI
Description: Classification and characterization of the lymphatic vasculature using non-contrast MRI.
Study: NCT00134082

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 mcg/kg/day starting on Day +6 until ANC is \>= 1000/mcL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2/day on Days -10, -7, and at weeks 4, 5, 6, and 7.
Study: NCT01999907

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo given in a 2ml dose by mouth at baseline.
Study: NCT01146951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rufinamide (E2080)
Description: Rufinamide tablets administered orally twice daily after breakfast and dinner. Treatment was divided into a Dose Titration Period (2 weeks) and a Dose Maintenance Period (10 weeks). As a general rule, the dose was increased by 1 step every 2 days until it reached the target maintenance dose determined by body weight at the start of the Observation Period.~Target maintenance dose:~15.0 - 30.0 kg: 1000 mg/day (5 tablets each in the morning and evening) 30.1 - 50.0 kg: 1800 mg/day (4 tablets in the morning and 5 in the evening) 50.1 - 70.0 kg: 2400 mg/day (6 tablets each in the morning and evening) \>= 70.1 kg: 3200 mg/day (8 tablets each in the morning and evening)
Study: NCT04163653

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test
Description: Cardiopulmonary exercise test, measurement of VO2 and heart rate.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test
Description: Cardiopulmonary exercise test, measurement of VO2 and heart rate.
Study: NCT02186782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate and Estradiol
Description: Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate and Placebo
Description: Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and placebo (for 5 consecutive days from day 2 of cycle)
Study: NCT02439905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: In dexmedetomidine group, dexmedetomidine infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
Study: NCT04806529

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator
Description: Biological/Vaccine: A dose of 0.5 mL saline for injection will be administrated to subjects randomized to receive the placebo
Study: NCT02439905

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: In normal saline group, normal saline infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
Study: NCT03117114

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff Vision assisted polypectomy
Description: EVD mounted to the tip of the endoscope, therefore EVD assisted polypectomy

Intervention type: OTHER
Group type: OTHER
Intervention: Standard polypectomy
Description: Absence of an EVD, standard polypectomy
Study: NCT01976871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine is FDA approved for the treatment of Restless Legs Syndrome at doses of 1 mg/24h, 2 mg/24h, and 3 mg/24h. The prescribed dose of rotigotine may be achieved using single or multiple patches. Subjects will titrate the dose based on discussions with the investigator.
Study: NCT01381471

Intervention type: DRUG
Intervention: fluticasone propionate/salmeterol xinafoate combination
Description: fluticasone propionate/salmeterol xinafoate combination
Study: NCT00780234

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluorescence bronchoscopy
Description: examination of the central airways with a bronchoscope. Both white light and fluorescent light will be used.
Study: NCT01146951

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rufinamide Matching Placebo tablets administered orally twice daily after breakfast and dinner for a total of 12 weeks.
Study: NCT03235726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI15106
Description: One capsule (single dose or repeat dose) of 30 mg of CCI15106 will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI15106
Description: One capsule (single dose or repeat dose) of 30 mg of CCI15106 will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI15106
Description: One capsule (single dose or repeat dose) of 30 mg of CCI15106 will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI15106
Description: One capsule (single dose or repeat dose) of 30 mg of CCI15106 will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule of placebo will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule of placebo will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule of placebo will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule of placebo will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
Study: NCT03498118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mL of bupivacaine 0.25%
Description: In the infiltration group, at the end of surgery, 30 mL of bupivacaine 0.25% was injected subcutaneously in the surgical wound (15 mL in each of the upper and lower sides) by the obstetrician before skin closure. Sam procedure was performed by the primary investigator after completion of surgery by pressing a covered spinal needle on both sides of the patient's abdomen.~In the TAP group, after completion of surgery, 20 mL of bupivacaine 0.25% was injected under direct visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mL of bupivacaine 0.25%
Description: In the infiltration group, at the end of surgery, 30 mL of bupivacaine 0.25% was injected subcutaneously in the surgical wound (15 mL in each of the upper and lower sides) by the obstetrician before skin closure. Sam procedure was performed by the primary investigator after completion of surgery by pressing a covered spinal needle on both sides of the patient's abdomen.~In the TAP group, after completion of surgery, 20 mL of bupivacaine 0.25% was injected under direct visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
Study: NCT02157012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The effectiveness of Xeljanz in rheumatoid arthritis patients
Study: NCT02771457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab at weeks 0,2, and 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab at weeks 0,4, and 8
Study: NCT00780234

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: fluorescence bronchoscopy
Description: examination of the central airways with a bronchoscope. Both white light and fluorescent light will be used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quantitative high resolution CT scan
Description: High resolution CT scan of the chest

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: quantitative high resolution CT scan
Description: High resolution CT scan of the chest
Study: NCT00134082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg/day on Day -3, -2, -1, and 0.
Study: NCT03011736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Description: Undergo parathyroidectomy
Study: NCT01335373

Intervention type: DRUG
Intervention: Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)
Description: Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed.
Study: NCT02771457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab at weeks 0 and 8
Description: For physicians who do not feel comfortable enrolling patients in a randomized trial of infliximab re-induction they will have the option of enrolling their patients in an arm that resumes maintenance therapy only instead at 0 and 8 weeks.
Study: NCT02668744

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Intervention
Description: The intervention consists of building edible gardens at each the eight participating and eligible schools. Educators will be provided to lead 18 gardening, nutrition and cooking lessons throughout the school year intervention to all 3-5th grade students. Nine gardening, nutrition, and cooking classes will be taught to parents every month. Garden Leadership Coalitions (GLCs), made up of parents, teachers and school staff, will be formed and training/resources provided to help with adoption of the program. Training and resources will be provided to the GLCs and teachers in the 2nd year to assist with sustainability.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention consists of building edible gardens at each the eight participating and eligible schools. Educators will be provided to lead 18 gardening, nutrition and cooking lessons throughout the school year intervention to all 3-5th grade students. Nine gardening, nutrition, and cooking classes will be taught to parents every month. Garden Leadership Coalitions (GLCs), made up of parents, teachers and school staff, will be formed and training/resources provided to help with adoption of the program. Training and resources will be provided to the GLCs and teachers in the 2nd year to assist with sustainability.
Study: NCT04539925

Intervention type: OTHER
Intervention: Acute coronary syndrome
Description: The effect of air pollution on acute coronary syndrome

Intervention type: OTHER
Intervention: Acute coronary syndrome
Description: The effect of air pollution on acute coronary syndrome
Study: NCT01814826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN4924
Description: MLN4924 intravenously (IV) in AML participants in a 28-day cycle:~* MLN4924 on Days 1, 3, and 5 for Cycle 1 and all subsequent cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine (IV) or subcutaneously in AML participants in a 28-day cycle:~- Azacitidine Days 1, 2, 3, 4, 5, 8, 9 in Cycle 1 and for all subsequent cycles
Study: NCT02379312

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Very low energy aerated beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal energy aerated beverage 1

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal energy aerated beverage 2

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal energy aerated beverage 3
Study: NCT03184116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual intervention
Description: Individual intervention based on a cognitive-behavioral program Reasoning \& Rehabilitation
Study: NCT02712281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autism MEAL Plan
Description: The Autism MEAL plan includes education on feeding issues and behavior management, and specific strategies to expand dietary diversity. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician. The first three sessions focus on understanding feeding problems and behavior management strategies in children with ASD.The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson.~The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Education
Description: The Parent Education study arm includes 10 sessions focusing on the following topics: understanding Autism Spectrum Disorder (ASD), clinical assessments for ASD, development in children with ASD, medical and genetic comorbidities in ASD, family and sibling issues, treatment alternatives, and education and treatment planning. The Parent Education arm does not include topics related to feeding problems or feeding specific interventions. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician.~Children randomized to Parent Education will be offered the Autism MEAL Plan after completing the 10-week randomized trial.
Study: NCT02227056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
Study: NCT04252248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacogen
Description: Intravenous (i.v.) infusion of 20 mg/m2 over 1 hour repeated daily for 5 days starting on day 1. Single repetition of cycle on day 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacogen
Description: Intravenous (i.v.) infusion of 20 mg/m2 over 1 hour repeated daily for 5 days starting on day 1. Single repetition of cycle on day 29.
Study: NCT03729661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nasal High Flow Therapy
Description: Use of Nasal High Flow Therapy during CT and treatment
Study: NCT03091595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg E4/3 mg DRSP
Description: 15 mg E4/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
Study: NCT03692247

Intervention type: OTHER
Group type: OTHER
Intervention: Smartphone-based Music Intervention
Description: The smartphone-based music intervention (Unwind) is a music protocol that gathers basic information from the patient including a 0-10 pain scale and 0-10 anxiety scale as well as recorded heart rate. Using these variables, a machine learning protocol pieces together a music intervention between 5-20 minutes long. The duration of the intervention can be controlled by the patient or experimenter. No identifying data is kept on the smartphone.
Study: NCT01127932

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation for substance abuse
Description: This active control provides detailed information about substance use, suicide risk, and depression to those enrolled.
Study: NCT00780234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIOGLITAZONE VS. PLACEBO 30 mg
Description: Patients will be randomized to receive either pioglitazone or placebo. Pioglitazone hydrochloride, a thiazolidinedione antidiabetic agent and a potent peroxisome proliferator-~activated receptor-gamma agonist. It is FDA approved for the treatment of Type II diabetes. It has been previously administered to non-diabetic subjects. The most common side effect of pioglitazone is fluid retention and modest weight gain. There is a potential risk that pioglitazone may cause an elevation in liver enzymes and more serious hepatotoxicity (rare). There is risk of edema and weight gain associated with pioglitazone therapy. 5% experienced peripheral edema in clinical trials. fluid retention may result in new onset heart failure or exacerbation of existing heart failure. Small risk of hypoglycemia, anemia, myalgia, bone fracture, headache, and macular retinal edema exists. There is insufficient information to confirm its safety in Pregnancy/Breastfeeding. Bladder cancer is more serious but rare.
Study: NCT03091595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mcg EE/3 mg DRSP
Description: 20 mcg EE/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
Study: NCT01127932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for suicide in Substance abuse
Description: The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
Study: NCT03525002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine
Description: In each FTO genotype group participants will be randomly receive bromocriptine or placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine
Description: In each FTO genotype group participants will be randomly receive bromocriptine or placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine
Description: In each FTO genotype group participants will be randomly receive bromocriptine or placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In each FTO genotype group participants will be randomly receive bromocriptine or placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In each FTO genotype group participants will be randomly receive bromocriptine or placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In each FTO genotype group participants will be randomly receive bromocriptine or placebo.
Study: NCT02938247

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High caloric, high protein ONS
Study: NCT02419378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Study: NCT02229786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buscopan® plus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buscopan®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo